Marc Siladi is a life sciences executive with a track record of driving scientific innovation from discovery through commercialization. He currently leads technical strategy, product development, and market expansion at Koneksa Health. Prior to Koneksa, Marc served as Chief Operating Officer at Strateos, where he led the development and commercialization of the world’s first robotic cloud laboratory, culminating in a successful exit for Strateos.
Marc has held senior roles at Gilead Sciences, Thermo Fisher Scientific, and Vertex Pharmaceuticals. At Gilead, he applied AI-driven logistics to optimize the supply chain for Remdesivir, the first FDA-approved COVID-19 treatment. As a protein biochemist at Vertex, he contributed to foundational advances in cystic fibrosis therapies targeting the genetic root of the disease.
Marc earned his undergraduate degree in Biochemistry from UC San Diego and graduate studies in Mathematics at Penn State. He is an inventor on seven patents spanning biologics, protein engineering, and nanotechnology, and has authored multiple publications. He also serves on the scientific advisory boards of several emerging life sciences companies.